(NASDAQ: CADL) Candel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.62%.
Candel Therapeutics's earnings in 2026 is -$38,182,000.On average, 8 Wall Street analysts forecast CADL's earnings for 2026 to be -$96,729,892, with the lowest CADL earnings forecast at -$165,098,573, and the highest CADL earnings forecast at -$59,220,140. On average, 8 Wall Street analysts forecast CADL's earnings for 2027 to be -$55,301,430, with the lowest CADL earnings forecast at -$95,470,045, and the highest CADL earnings forecast at $24,610,967.
In 2028, CADL is forecast to generate $59,527,778 in earnings, with the lowest earnings forecast at -$61,732,510 and the highest earnings forecast at $204,578,667.